Amarin’s Vascepa, AstraZeneca’s Epanova theoretical cardiovascular risk reduction class effect possibly stifled

A potential class efficacy/safety effect is possible as both therapies are approved for hypertriglyceremia.



  • Vascepa versus Epanova